US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
WO1995035277A1
(en)
*
|
1994-06-20 |
1995-12-28 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
JP3023179B2
(ja)
*
|
1995-09-27 |
2000-03-21 |
シェーリング コーポレイション |
立体選択的微生物還元プロセス
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
EP0766962A3
(de)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Behandlung der Atherosclerose
|
MY114803A
(en)
*
|
1995-10-31 |
2003-01-31 |
Schering Corp |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
WO1997016424A1
(en)
*
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
DE69734321T2
(de)
*
|
1996-02-23 |
2006-08-10 |
Eli Lilly And Co., Indianapolis |
Non-peptidische vasopressin via antagonisten
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
ATE297892T1
(de)
*
|
1998-12-07 |
2005-07-15 |
Schering Corp |
Verfahren zur herstellung von azetidinonen
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
WO2000038722A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
|
AU3103800A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
|
ATE228012T1
(de)
|
1998-12-23 |
2002-12-15 |
Searle Llc |
Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
WO2000038725A1
(en)
*
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations for cardiovascular indications
|
WO2000038724A1
(en)
*
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
WO2000038726A1
(en)
*
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
EA200100707A1
(ru)
|
1998-12-23 |
2001-12-24 |
Джи.Ди.Сирл Ллс |
Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний
|
US6569905B1
(en)
|
1998-12-23 |
2003-05-27 |
G.D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
CA2367289C
(en)
|
1999-04-05 |
2008-02-12 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
US20020061888A1
(en)
*
|
2000-03-10 |
2002-05-23 |
Keller Bradley T. |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
WO2001068637A2
(en)
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
WO2002036124A2
(en)
*
|
2000-10-30 |
2002-05-10 |
Schering Corporation |
Treatment and method using loratadine and montelukast
|
TR200402758T4
(tr)
*
|
2000-12-20 |
2004-11-22 |
Schering Corporation |
Hipokolesterolemik ajanlar olarak faydalı şekerle ikame edilen 2-azetidinonlar.
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1593670B1
(de)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
Hydroxysubstituierte 2-Azetidinone verwendbar als Hypocholesterolemische Arzneimittel
|
EP1510521A1
(de)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
|
WO2002050027A1
(de)
*
|
2000-12-21 |
2002-06-27 |
Aventis Pharma Deutschland Gmbh |
Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
|
IL156552A0
(en)
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
EP1671650A1
(de)
*
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Kombinationen von einem Hemmer der Sterol-Absorption und Nicotinsäure zur Behandlung von kardiovaskulären Indikationen
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
EP1911462A3
(de)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
|
RS51449B
(sr)
*
|
2001-01-26 |
2011-04-30 |
Schering Corporation |
Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
|
RS50406B
(sr)
*
|
2001-01-26 |
2009-12-31 |
Schering Corporation, |
Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
PT1353694E
(pt)
*
|
2001-01-26 |
2008-03-12 |
Schering Corp |
Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares
|
CA2434436A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Teddy Kosoglou |
Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
|
SI1363668T1
(sl)
*
|
2001-01-26 |
2007-12-31 |
Schering Corp |
Kombinacija sekvestranta(-ov) in zaviralca(-ev) absorpcije sterola ter zdravljenje vaskularnih indikacij
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
TWI291957B
(en)
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
ATE305459T1
(de)
*
|
2001-03-28 |
2005-10-15 |
Schering Corp |
Verfahren für die enantioselektive synthese von azetidinon-zwischenprodukten
|
CA2447884A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
EP1859796A3
(de)
*
|
2001-09-21 |
2008-07-02 |
Schering Corporation |
Behandlung von xanthom mit azetidinon-derivaten als hemmer der sterol absorption
|
ATE345793T1
(de)
*
|
2001-09-21 |
2006-12-15 |
Schering Corp |
Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
MXPA04003524A
(es)
*
|
2001-11-02 |
2004-07-23 |
Searle Llc |
Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
|
EP1451138A4
(de)
*
|
2001-11-09 |
2005-06-15 |
Atherogenics Inc |
Verfahren zur umkehrung und prävention von kardiovaskulären erkrankungen
|
AU2002361811A1
(en)
|
2001-12-19 |
2003-07-09 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
EP1465854A4
(de)
*
|
2001-12-19 |
2005-06-08 |
Atherogenics Inc |
Chalconderivate und deren verwendung zur behandlung von krankheiten
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
AU2003207431A1
(en)
|
2002-01-17 |
2003-09-02 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
WO2003074101A1
(en)
*
|
2002-02-28 |
2003-09-12 |
Eli Lilly And Company |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
PL374860A1
(en)
|
2002-07-09 |
2005-11-14 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
CA2493614C
(en)
*
|
2002-07-30 |
2011-09-13 |
Karykion Inc. |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
AU2003303239A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
US7235543B2
(en)
*
|
2003-03-07 |
2007-06-26 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ATE418551T1
(de)
*
|
2003-03-07 |
2009-01-15 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
CA2517573C
(en)
*
|
2003-03-07 |
2011-12-06 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
WO2004099132A2
(en)
*
|
2003-05-05 |
2004-11-18 |
Ranbaxy Laboratories Limited |
Process for the preparation of trans-isomers of diphenylazetidinone derivatives
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
EP2319843B1
(de)
*
|
2003-05-30 |
2013-04-03 |
Ranbaxy Laboratories Limited |
Substituirte Pyrrolderivate und Ihre Verwendung als HMG-CO-Hemmer
|
US20060148721A1
(en)
*
|
2003-06-06 |
2006-07-06 |
Erondu Ngozi E |
Combination therapy for the treatment of dyslipidemia
|
WO2005009951A2
(en)
*
|
2003-07-24 |
2005-02-03 |
Merck & Co., Inc. |
Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
|
AU2003259547A1
(en)
*
|
2003-07-31 |
2005-02-14 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
EP1522541A1
(de)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Neue hypocholesterolemische Verbindungen
|
WO2005042692A2
(en)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
EP1918000A2
(de)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
|
JP2007510659A
(ja)
*
|
2003-11-05 |
2007-04-26 |
シェーリング コーポレイション |
脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
|
CA2545058A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Microbia, Inc. |
4-biarylyl-1-phenylazetidin-2-ones
|
WO2005049592A1
(en)
*
|
2003-11-24 |
2005-06-02 |
Hetero Drugs Limited |
A novel process for ezetimibe intermediate
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
CN100471835C
(zh)
|
2003-12-23 |
2009-03-25 |
默克公司 |
抗高胆固醇血症化合物
|
SA04250427A
(ar)
*
|
2003-12-23 |
2005-12-03 |
استرازينيكا ايه بي |
مشتقات ثاني فينيل أزيتيدون
|
WO2005069900A2
(en)
*
|
2004-01-16 |
2005-08-04 |
Merck & Co., Inc. |
Npc1l1 (npc3) and methods of identifying ligands thereof
|
JP5697296B2
(ja)
|
2004-03-05 |
2015-04-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
CA2567149A1
(en)
*
|
2004-05-21 |
2005-12-01 |
Sanofi-Aventis Deutschland Gmbh |
Method for producing 1,4-diphenyl azetidinone derivatives
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
WO2006004903A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Atherogenics, Inc. |
1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
GT200500246A
(es)
*
|
2004-09-09 |
2006-04-17 |
|
Combinacion de compuestos organicos
|
MX2007003732A
(es)
*
|
2004-09-29 |
2007-04-23 |
Schering Corp |
Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
|
KR101351209B1
(ko)
|
2004-12-03 |
2014-02-06 |
머크 샤프 앤드 돔 코포레이션 |
Cb1 길항제로서 치환된 피페라진
|
JP2008523807A
(ja)
*
|
2004-12-15 |
2008-07-10 |
シェーリング コーポレイション |
コレステロール吸収インヒビターについての機能アッセイ
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
BRPI0609614A2
(pt)
|
2005-04-04 |
2010-04-20 |
Univ Pontificia Catolica Chile |
uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar
|
TW200726746A
(en)
*
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
WO2006122117A2
(en)
*
|
2005-05-09 |
2006-11-16 |
Microbia, Inc. |
Organometal benzenephosphonate coupling agents
|
US20080200669A1
(en)
*
|
2005-05-11 |
2008-08-21 |
Microbia, Inc. |
Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
BRPI0611415A2
(pt)
*
|
2005-05-25 |
2010-09-08 |
Microbia Inc |
ácidos fosfÈnicos de 4-(bifenilil)azetidin-2-ona e processo para a produção dos mesmos
|
AU2006259646A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
US7635705B2
(en)
*
|
2005-06-20 |
2009-12-22 |
Schering Corporation |
Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
EP1893570A4
(de)
*
|
2005-06-22 |
2009-12-23 |
Reddy Manne Satynarayana |
Verbessertes verfahren zur herstellung von ezetimib
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
EP1741427A1
(de)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
BRPI0605934A2
(pt)
|
2005-09-08 |
2009-05-26 |
Teva Pharma |
processos para a preparação de ( 3r, 4s) - 4 - ( (4-benziloxi ) fenil ) - 1 - ( 4 - fluorofenil ) - 3 - ( (s) - 3 - ( 4 - fluorofenil ) - 3 - hidroxipropil) - 2 - azetidinona, um intermediário para a sìntese da ezetimiba
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
BRPI0617621A2
(pt)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combinação de compostos orgánicos
|
SG166829A1
(en)
*
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
HUP0501164A2
(en)
*
|
2005-12-20 |
2007-07-30 |
Richter Gedeon Nyrt |
New industrial process for the production of ezetimibe
|
US20070161578A1
(en)
*
|
2005-12-21 |
2007-07-12 |
Hwa Joyce J |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
|
US20090227786A1
(en)
*
|
2005-12-22 |
2009-09-10 |
Ana Gavalda I Escude |
Processes for preparing intermediate compounds useful for the preparation of ezetimibe
|
BRPI0706623A2
(pt)
|
2006-01-18 |
2011-04-12 |
Schering Corp |
moduladores de receptor canabinóide
|
WO2007094480A1
(ja)
*
|
2006-02-16 |
2007-08-23 |
Kotobuki Pharmaceutical Co., Ltd. |
光学活性アルコールを製造する方法
|
US7910698B2
(en)
*
|
2006-02-24 |
2011-03-22 |
Schering Corporation |
NPC1L1 orthologues
|
WO2007103453A1
(en)
*
|
2006-03-06 |
2007-09-13 |
Teva Pharmaceutical Industries Ltd. |
Ezetimibe compositions
|
AR059838A1
(es)
*
|
2006-03-14 |
2008-04-30 |
Ranbaxy Lab Ltd |
Formulaciones para dosis estabilizantes de estatina
|
EP2004639A2
(de)
*
|
2006-04-10 |
2008-12-24 |
Teva Pharmaceutical Industries Ltd |
Verfahren zur synthese von azetinidon
|
TW200811098A
(en)
*
|
2006-04-27 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
BRPI0714361A2
(pt)
*
|
2006-07-14 |
2013-03-26 |
Ranbaxy Lab Ltd |
polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
|
KR20080053948A
(ko)
*
|
2006-08-29 |
2008-06-16 |
테바 파마슈티컬 인더스트리즈 리미티드 |
(3r,4s)-4-(4-히드록시-보호된-페닐)-1-(4-플루오로페닐)-3-[3-(4-플루오로페닐)-3-옥소프로필]아제티딘-2-온의정제 방법
|
MX2009002398A
(es)
*
|
2006-09-05 |
2009-03-16 |
Schering Corp |
Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
|
MX2009002922A
(es)
|
2006-09-15 |
2009-04-01 |
Schering Corp |
Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
|
MX2009002918A
(es)
*
|
2006-09-15 |
2009-03-31 |
Schering Corp |
Derivados azetidinona y sus metodos de uso.
|
WO2008033431A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
|
MX2009002921A
(es)
*
|
2006-09-15 |
2009-04-01 |
Schering Corp |
Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
|
CN101541795A
(zh)
*
|
2006-09-15 |
2009-09-23 |
先灵公司 |
用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
AU2007342603A1
(en)
*
|
2006-12-20 |
2008-07-17 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
WO2008079398A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Aegerion Pharmaceuticals, Inc. |
Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
|
EP1939174A1
(de)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Einschlusskomplex von Ezetimib und einem Cyclodextrin und Verfahren zu seiner Herstellung
|
CN102285906B
(zh)
*
|
2007-01-24 |
2014-11-19 |
克尔克公司 |
依泽替米贝的制备方法和其的衍生物
|
WO2008096372A2
(en)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Process for preparing highly pure ezetimibe using novel intermediates
|
WO2008104875A1
(en)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones as cholesterol absorption inhibitors
|
EP2133347A4
(de)
|
2007-03-06 |
2010-03-17 |
Teijin Pharma Ltd |
1-biarylazetidinonderivate
|
EP2134169A2
(de)
|
2007-03-09 |
2009-12-23 |
Indigene Pharmaceuticals Inc. |
Kombination von metformid-r-(+)-lipoat und antihyperlipidämika für die behandlung von diabetes-hyperglykämie und diabetesbedingte komplikationen
|
WO2008123953A1
(en)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compound
|
US20100197564A1
(en)
*
|
2007-04-19 |
2010-08-05 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
US20090047716A1
(en)
*
|
2007-06-07 |
2009-02-19 |
Nurit Perlman |
Reduction processes for the preparation of ezetimibe
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
CN101790521A
(zh)
*
|
2007-06-28 |
2010-07-28 |
英特维特国际股份有限公司 |
作为cb1拮抗剂的取代哌嗪
|
NZ582249A
(en)
*
|
2007-06-28 |
2012-06-29 |
Intervet Int Bv |
Substituted piperazines as cb1 antagonists
|
JP2010534644A
(ja)
*
|
2007-07-27 |
2010-11-11 |
シプラ・リミテッド |
医薬組成物およびその製造方法
|
WO2009024889A2
(en)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
|
WO2009032264A1
(en)
*
|
2007-08-30 |
2009-03-12 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing intermediates of ezetimibe by microbial reduction
|
WO2009027785A2
(en)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
1, 3-oxazole derivatives as cetp inhibitors
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
ES2639995T3
(es)
|
2007-12-10 |
2017-10-31 |
Ratiopharm Gmbh |
Formulación farmacéutica que comprende ezetimiba
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(de)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetiminverfahren und -zusammensetzung
|
EP2307053A2
(de)
*
|
2008-06-06 |
2011-04-13 |
Nicox S.A. |
Zusammensetzungen mit atorvastatin 4- (nitrooxy) butylester und einem hypolipidämischen arzneimittel
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
CN102186972B
(zh)
|
2008-08-29 |
2014-08-20 |
科德克希思公司 |
用于立体选择性生产(4s)-3-[(5s)-5-(4-氟苯基)-5-羟基戊酰基]-4-苯基-1,3-噁唑烷-2-酮的酮还原酶多肽
|
CN102202661A
(zh)
|
2008-11-14 |
2011-09-28 |
博米·P·弗莱姆罗兹 |
降低循环氧化低密度脂蛋白-β-2-糖蛋白1复合物以治疗动脉粥样硬化的方法
|
EP2204170A1
(de)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
EP2216016A1
(de)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst
|
US9212175B2
(en)
|
2009-03-06 |
2015-12-15 |
Lipideon Biotechnology Ag |
Pharmaceutical hypocholesterolemic compositions
|
ATE536172T1
(de)
|
2009-03-13 |
2011-12-15 |
Sanovel Ilac Sanayi Ve Ticaret As |
Ezetimibzusammensetzungen
|
US9040688B2
(en)
|
2009-03-31 |
2015-05-26 |
Lupin Limited |
Intermediates in the preparation of 1,4-diphenyl azetidinone
|
CA2757722C
(en)
|
2009-04-01 |
2018-05-22 |
Matrix Laboratories Ltd. |
Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
|
WO2011002422A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility enhancing pharmaceutical formulation
|
WO2011002424A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility and stability enchancing pharmaceutical formulation
|
WO2011019326A2
(en)
|
2009-07-02 |
2011-02-17 |
Mahmut Bilgic |
Solubility and stability enchancing pharmaceutical formulation
|
CN101993403B
(zh)
*
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
EP2467473B1
(de)
|
2009-08-19 |
2016-03-23 |
Codexis, Inc. |
Ketoreduktase-polypeptide zur herstellung von phenylephrin
|
CA2790899C
(en)
|
2010-02-24 |
2018-12-18 |
Relypsa, Inc. |
Polyimidazoles for use as bile acid sequestrants
|
DE112011100657T5
(de)
|
2010-02-24 |
2013-02-28 |
Relypsa, Inc. |
Amin-polymere zur verwendung als gallensäuresequestriermittel
|
CN102858817B
(zh)
|
2010-02-24 |
2015-09-02 |
瑞立普萨公司 |
用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
|
EP2368543A1
(de)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
|
DK2561069T3
(en)
|
2010-04-23 |
2017-05-01 |
Alexion Pharma Inc |
Enzyme for lysosomal storage disease
|
HUE026367T2
(en)
|
2010-05-04 |
2016-06-28 |
Codexis Inc |
Biocatalysts of ezetimibe synthesis
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
PL2977057T3
(pl)
|
2010-09-09 |
2020-06-01 |
Alexion Pharmaceuticals, Inc. |
Izolowana rekombinowana ludzka lizosomalna N-glikozylowana kwaśna lipaza
|
ES2687027T3
(es)
|
2010-11-08 |
2018-10-23 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepáticas
|
CN103228270B
(zh)
|
2010-11-08 |
2016-02-10 |
阿尔比里奥公司 |
含ibat抑制剂和胆汁酸结合剂的药物组合
|
WO2012076030A1
(en)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
WO2012112681A1
(en)
|
2011-02-15 |
2012-08-23 |
Shire Human Genetic Therapies, Inc. |
Methods for treating lysosomal acid lipase deficiency
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
DK2844233T3
(da)
|
2012-05-01 |
2020-07-13 |
Althera Life Sciences Llc |
Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
WO2015066252A1
(en)
|
2013-11-04 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions thereof, and methods of use
|
WO2015092448A1
(en)
|
2013-12-18 |
2015-06-25 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
CA2950390C
(en)
|
2014-05-30 |
2020-09-22 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
CN105294426B
(zh)
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
AU2016233485B2
(en)
|
2015-03-13 |
2021-05-20 |
Esperion Therapeutics, Inc. |
Fixed dose combinations and formulations comprising ETC1002 and Ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
CN109791797B
(zh)
|
2016-12-05 |
2023-05-02 |
智慧芽信息科技(苏州)有限公司 |
在大数据库中根据化学结构相似性搜索和显示可用信息的系统、装置和方法
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(de)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Pharmazeutische zusammensetzung mit ezetimibe
|
EP3740653A4
(de)
|
2018-01-16 |
2021-10-20 |
Q.E.D. Environmental Systems, Inc. |
Flüssigkeitsstandüberwachungssystem und -verfahren mit einem drucksensorsystem mit aufblasbarem/zusammenfaltbarem beutel
|
WO2020191141A1
(en)
|
2019-03-20 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
|
CA3133002A1
(en)
|
2019-03-20 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
|
WO2021019499A1
(en)
|
2019-07-31 |
2021-02-04 |
TECNIMEDE - Sociedade Técnico-medicinal, SA |
Solid oral multiple-unit immediate release compositions, methods and uses thereof
|
EP4188338A1
(de)
|
2020-07-27 |
2023-06-07 |
KRKA, d.d., Novo mesto |
Zweischichtige tablette mit ezetimib und atorvastatin
|
AU2022291920A1
(en)
*
|
2021-06-17 |
2023-12-21 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Hybutimibe intermediate and preparation method therefor
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|